Report cover image

Global Biosimilar Therapeutic Peptides Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 100 Pages
SKU # APRC20354968

Description

Summary

According to APO Research, The global Biosimilar Therapeutic Peptides market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Biosimilar Therapeutic Peptides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Biosimilar Therapeutic Peptides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Biosimilar Therapeutic Peptides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global companies of Biosimilar Therapeutic Peptides include Takeda Pharmaceuticals, Sanofi, Novartis AG, li Lilly and Company, Pfizer, GlaxoSmithKline, Amgen, AstraZeneca and Teva Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Biosimilar Therapeutic Peptides, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Therapeutic Peptides.

The Biosimilar Therapeutic Peptides market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biosimilar Therapeutic Peptides market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Biosimilar Therapeutic Peptides Segment by Company

Takeda Pharmaceuticals
Sanofi
Novartis AG
li Lilly and Company
Pfizer
GlaxoSmithKline
Amgen
AstraZeneca
Teva Pharmaceuticals
Novo Nordisk

Biosimilar Therapeutic Peptides Segment by Type

Innovative
Generic

Biosimilar Therapeutic Peptides Segment by Application

Cancer
Metabolic Disorders
Dermatology
Gastrointestinal Disorders
Cardiovascular
Central Nervous Systems
Others

Biosimilar Therapeutic Peptides Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Therapeutic Peptides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Therapeutic Peptides and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Therapeutic Peptides.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Biosimilar Therapeutic Peptides companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report

Table of Contents

100 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.3 Global Biosimilar Therapeutic Peptides Market Size Overview by Region 2020 VS 2024 VS 2031
1.4 Global Biosimilar Therapeutic Peptides Market Size by Region (2020-2031)
1.4.1 Global Biosimilar Therapeutic Peptides Market Size by Region (2020-2025)
1.4.2 Global Biosimilar Therapeutic Peptides Market Size by Region (2026-2031)
1.5 Key Regions Biosimilar Therapeutic Peptides Market Size (2020-2031)
1.5.1 North America Biosimilar Therapeutic Peptides Market Size Growth Rate (2020-2031)
1.5.2 Europe Biosimilar Therapeutic Peptides Market Size Growth Rate (2020-2031)
1.5.3 Asia-Pacific Biosimilar Therapeutic Peptides Market Size Growth Rate (2020-2031)
1.5.4 South America Biosimilar Therapeutic Peptides Market Size Growth Rate (2020-2031)
1.5.5 Middle East & Africa Biosimilar Therapeutic Peptides Market Size Growth Rate (2020-2031)
2 Biosimilar Therapeutic Peptides Market by Type
2.1 Type Introduction
2.1.1 Innovative
2.1.2 Generic
2.2 Global Biosimilar Therapeutic Peptides Market Size by Type
2.2.1 Global Biosimilar Therapeutic Peptides Market Size Overview by Type (2020-2031)
2.2.2 Global Biosimilar Therapeutic Peptides Historic Market Size Review by Type (2020-2025)
2.2.3 Global Biosimilar Therapeutic Peptides Market Size Forecasted by Type (2026-2031)
2.3 Global Biosimilar Therapeutic Peptides Market Size by Regions
2.3.1 North America Biosimilar Therapeutic Peptides Market Size Breakdown by Type (2020-2025)
2.3.2 Europe Biosimilar Therapeutic Peptides Market Size Breakdown by Type (2020-2025)
2.3.3 Asia-Pacific Biosimilar Therapeutic Peptides Market Size Breakdown by Type (2020-2025)
2.3.4 South America Biosimilar Therapeutic Peptides Market Size Breakdown by Type (2020-2025)
2.3.5 Middle East and Africa Biosimilar Therapeutic Peptides Market Size Breakdown by Type (2020-2025)
3 Biosimilar Therapeutic Peptides Market by Application
3.1 Type Introduction
3.1.1 Cancer
3.1.2 Metabolic Disorders
3.1.3 Dermatology
3.1.4 Gastrointestinal Disorders
3.1.5 Cardiovascular
3.1.6 Central Nervous Systems
3.1.7 Others
3.2 Global Biosimilar Therapeutic Peptides Market Size by Application
3.2.1 Global Biosimilar Therapeutic Peptides Market Size Overview by Application (2020-2031)
3.2.2 Global Biosimilar Therapeutic Peptides Historic Market Size Review by Application (2020-2025)
3.2.3 Global Biosimilar Therapeutic Peptides Market Size Forecasted by Application (2026-2031)
3.3 Global Biosimilar Therapeutic Peptides Market Size by Regions
3.3.1 North America Biosimilar Therapeutic Peptides Market Size Breakdown by Application (2020-2025)
3.3.2 Europe Biosimilar Therapeutic Peptides Market Size Breakdown by Application (2020-2025)
3.3.3 Asia-Pacific Biosimilar Therapeutic Peptides Market Size Breakdown by Application (2020-2025)
3.3.4 South America Biosimilar Therapeutic Peptides Market Size Breakdown by Application (2020-2025)
3.3.5 Middle East and Africa Biosimilar Therapeutic Peptides Market Size Breakdown by Application (2020-2025)
4 Global Market Dynamics
4.1 Biosimilar Therapeutic Peptides Industry Trends
4.2 Biosimilar Therapeutic Peptides Industry Drivers
4.3 Biosimilar Therapeutic Peptides Industry Opportunities and Challenges
4.4 Biosimilar Therapeutic Peptides Industry Restraints
5 Competitive Insights by Company
5.1 Global Top Players by Biosimilar Therapeutic Peptides Revenue (2020-2025)
5.2 Global Biosimilar Therapeutic Peptides Industry Company Ranking, 2023 VS 2024 VS 2025
5.3 Global Biosimilar Therapeutic Peptides Key Company Headquarters & Area Served
5.4 Global Biosimilar Therapeutic Peptides Company, Product Type & Application
5.5 Global Biosimilar Therapeutic Peptides Company Commercialization Time
5.6 Market Competitive Analysis
5.6.1 Global Biosimilar Therapeutic Peptides Market CR5 and HHI
5.6.2 Global Top 5 and 10 Biosimilar Therapeutic Peptides Players Market Share by Revenue in 2024
5.6.3 2024 Biosimilar Therapeutic Peptides Tier 1, Tier 2, and Tier 3
6 Company Profiles
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Comapny Information
6.1.2 Takeda Pharmaceuticals Business Overview
6.1.3 Takeda Pharmaceuticals Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2020-2025)
6.1.4 Takeda Pharmaceuticals Biosimilar Therapeutic Peptides Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments
6.2 Sanofi
6.2.1 Sanofi Comapny Information
6.2.2 Sanofi Business Overview
6.2.3 Sanofi Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2020-2025)
6.2.4 Sanofi Biosimilar Therapeutic Peptides Product Portfolio
6.2.5 Sanofi Recent Developments
6.3 Novartis AG
6.3.1 Novartis AG Comapny Information
6.3.2 Novartis AG Business Overview
6.3.3 Novartis AG Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2020-2025)
6.3.4 Novartis AG Biosimilar Therapeutic Peptides Product Portfolio
6.3.5 Novartis AG Recent Developments
6.4 li Lilly and Company
6.4.1 li Lilly and Company Comapny Information
6.4.2 li Lilly and Company Business Overview
6.4.3 li Lilly and Company Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2020-2025)
6.4.4 li Lilly and Company Biosimilar Therapeutic Peptides Product Portfolio
6.4.5 li Lilly and Company Recent Developments
6.5 Pfizer
6.5.1 Pfizer Comapny Information
6.5.2 Pfizer Business Overview
6.5.3 Pfizer Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2020-2025)
6.5.4 Pfizer Biosimilar Therapeutic Peptides Product Portfolio
6.5.5 Pfizer Recent Developments
6.6 GlaxoSmithKline
6.6.1 GlaxoSmithKline Comapny Information
6.6.2 GlaxoSmithKline Business Overview
6.6.3 GlaxoSmithKline Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2020-2025)
6.6.4 GlaxoSmithKline Biosimilar Therapeutic Peptides Product Portfolio
6.6.5 GlaxoSmithKline Recent Developments
6.7 Amgen
6.7.1 Amgen Comapny Information
6.7.2 Amgen Business Overview
6.7.3 Amgen Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2020-2025)
6.7.4 Amgen Biosimilar Therapeutic Peptides Product Portfolio
6.7.5 Amgen Recent Developments
6.8 AstraZeneca
6.8.1 AstraZeneca Comapny Information
6.8.2 AstraZeneca Business Overview
6.8.3 AstraZeneca Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2020-2025)
6.8.4 AstraZeneca Biosimilar Therapeutic Peptides Product Portfolio
6.8.5 AstraZeneca Recent Developments
6.9 Teva Pharmaceuticals
6.9.1 Teva Pharmaceuticals Comapny Information
6.9.2 Teva Pharmaceuticals Business Overview
6.9.3 Teva Pharmaceuticals Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2020-2025)
6.9.4 Teva Pharmaceuticals Biosimilar Therapeutic Peptides Product Portfolio
6.9.5 Teva Pharmaceuticals Recent Developments
6.10 Novo Nordisk
6.10.1 Novo Nordisk Comapny Information
6.10.2 Novo Nordisk Business Overview
6.10.3 Novo Nordisk Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2020-2025)
6.10.4 Novo Nordisk Biosimilar Therapeutic Peptides Product Portfolio
6.10.5 Novo Nordisk Recent Developments
7 North America
7.1 North America Biosimilar Therapeutic Peptides Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2 North America Biosimilar Therapeutic Peptides Market Size by Country (2020-2025)
7.3 North America Biosimilar Therapeutic Peptides Market Size Forecast by Country (2026-2031)
8 Europe
8.1 Europe Biosimilar Therapeutic Peptides Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2 Europe Biosimilar Therapeutic Peptides Market Size by Country (2020-2025)
8.3 Europe Biosimilar Therapeutic Peptides Market Size Forecast by Country (2026-2031)
9 Asia-Pacific
9.1 Asia-Pacific Biosimilar Therapeutic Peptides Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2 Asia-Pacific Biosimilar Therapeutic Peptides Market Size by Country (2020-2025)
9.3 Asia-Pacific Biosimilar Therapeutic Peptides Market Size Forecast by Country (2026-2031)
10 South America
10.1 South America Biosimilar Therapeutic Peptides Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2 South America Biosimilar Therapeutic Peptides Market Size by Country (2020-2025)
10.3 South America Biosimilar Therapeutic Peptides Market Size Forecast by Country (2026-2031)
11 Middle East & Africa
11.1 Middle East & Africa Biosimilar Therapeutic Peptides Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2 Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Country (2020-2025)
11.3 Middle East & Africa Biosimilar Therapeutic Peptides Market Size Forecast by Country (2026-2031)
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.